Generic Drugs Market in Japan Growth Report 2015-2019

A generic drug is a duplicate of brand-name drugs and has the same dosage form, active ingredient(s), potency, route of administration, quality, and intended use as that of branded drugs. Generic drugs enter the market once the patent protection of the original developer expires. Generally, the cost of generic drugs is 50-70 percent lower than that of their brand-name counterparts, while meeting the very same standards of safety, quality, and efficacy as the innovator drugs. Generic drugs help the manufacturer by eliminating the need to develop and market a new drug. As the patent approaches expiration, manufacturers can apply to the FDA for approval to manufacture and sell generic versions of the drug. Generic drugs are equal to and within the bioequivalence range of branded drugs.

Analysts forecast the Generic Drugs market in Japan to grow at a CAGR of 8.16 percent over the period 2014-2019.

The Generic Drugs market in Japan can be divided into three segments: Generic Prescription Medicines, Super Generics, and Biosimilars. This report covers the present scenario and the growth prospects of the Generic Drugs market in Japan for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the following segments:

  • Generic Prescription Medicines
  • Super Generics
  • Biosimilars

Generic Drugs market in Japan 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape of the Generic Drugs market in Japan and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors

  • Meiji Seika Pharma
  • Nichi-Iko Pharmaceutical
  • Nipro Pharma
  • Sawai Pharmaceuticals
  • Teva Pharmaceutical Industries
  • Towa Pharmaceutical

Other Prominent Vendors

  • Actavis
  • Daiichi Sankyo
  • Daito Pharmaceutical
  • Eisai
  • Fuji Pharma
  • GlaxoSmithKline
  • Hikari Pharmaceutical
  • Hospira
  • Mylan
  • Nihon Generic
  • Nippon Chemipher
  • Nippon Kayaku
  • Nissin Pharmaceutical
  • Ohara Pharmaceutical
  • Pfizer
  • Sandoz
  • Taiyo Yakuhin
  • Takeda Pharmaceutical
  • Zensei Pharmaceutical Industries

Market Driver

  • Increase in Number of Patent Expiries

Market Challenge

  • Intense Competition among Vendors

Market Trend

  • Increase in M&A

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Have any Query on the Report get your Queries Resolved at .

(Prices start at US $2500 for a single user PDF)



Related Reports

Global Preventable Vaccines Market 2015-2019

Vaccines can be defined as a product that stimulates a person's immune system to produce immunity to a specific disease, thereby protecting the person from that disease. According to the CDC, vaccines are usually administered through needle injections, but can also be administered orally or sprayed into the nose. Vaccines can be used for both adults and infants and adolescents. Pediatric vaccines are used for the immunization of children to give protection against various infectious diseases such as diphtheria, influenza, hepatitis, pneumococcal diseases, and meningococcal diseases.

Cystic Fibrosis Market in Europe 2015-2019

Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited disease. The primary symptoms of cystic fibrosis include high salt content in the sweat, breathing difficulties, secretion of abnormally viscous mucus, respiratory complications, difficulties related to digestion, and growth anomalies. Cystic fibrosis is one of the most common genetic disorders observed in Caucasian children. Rare diseases are those that affect less than 5 patients per 10,000, as defined in the EU by Rare Disease UK.